Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

Turning Point Therapeutics and Almac Diagnostic Services recently announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine whether cancer patients are

German molecular diagnostics firm Curetis said recently that it will receive €6.5 million ($7.3 million) in gross proceeds under two financing facilities.

NeoGenomics said after the close of the market recently that it has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.

Qiagen reported after the close of the market recently that its first quarter revenues grew nearly 2 percent year over year as the firm fell short of analysts topline estimates but beat expectations on the bottom line. For the three months

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

On May 20, 2019, Thermo Fisher Scientific announced that it is investing more than $50 million into its global bioproduction capabilities. The expansion will provide additional capacity for manufacturing single-use bioprocess container (BPC)

Velano Vascular has secured $10 million as the initial tranche of a growth financing to fuel commercialization and the launch of new vascular access solutions. But perhaps most telling about this funding news is the notable investors who kic

Schaffhausen, Switzerland-based Physeon is trying to bring its Veinplicity device to the U.S. market. The device is designed to make veins easier to access on the first stick, preventing patients from being treated as pincushions.

Atellica Solution Immunoassay Clinical Chemistry Analyzers Atellica Solution is a multi analyzer system for in vitro diagnostic testing of clinical specimens. It offers unprecedented flexibility with over 300 configurations. Components can

Point-of-care (POC) testing is a rapidly growing market. As healthcare starts to shift toward consumers, the demand for tests that can be performed anywhere the patient is located, is increasing. With the promise to reduce costs and give qui